Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
- Early lymphoid lesions
- in situ follicular lymphoma
- intrafollicular neoplasia
- early lesions in B-cell lymphomas
- B-cell lymphomas
Early neoplastic or preneoplastic lesions in follicular lymphoma (FL) and in mantle cell lymphoma have been provisionally termed as ‘intrafollicular neoplasia’/in situ lymphoma by the 2008 WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.1–3 Interestingly, besides FL, neoplastic lesions restricted to the follicle have been described for other germinal centre (GC)-derived B-cell lymphomas.4 ,5
‘Intrafollicular neoplasia’/ ‘in situ’ follicular lymphoma: immunohistochemical, molecular and clinical evidence
In situ FL
The term ‘intrafollicular neoplasia’/‘in situ’ lymphoma has been adopted to define an early lymphoid neoplasia with an ‘intrafollicular’ growth pattern without invasion of surrounding structures.6 The term, originally coined for FL, properly applies when the neoplastic cells are localised in the ‘place’ that is occupied by the normal counterpart of the tumour cell. In situ FL is derived from GC B cells and displays t (14;18) (q32;q21), the genetic hallmark and initiating event of FL pathogenesis. This early lesion has an uncertain clinical behaviour and unknown risk of progression to overt lymphoma.
Table 1 shows histologic and immunophenotypic criteria to diagnose in situ FL and to distinguish it from overt FL with partial lymph node involvement.7 Immunohistologically, GC B cells of the follicles affected by in situ FL show strongly positive staining for BCL2 and CD10. They are also positive for other B-cell markers including CD20 and BCL6, but not IgD. The BCL2+ and CD10+ cells are confined to GCs and are not seen outside the follicles6 (figure 1).
Funding This work was supported in part by funds from the Ministero della Salute, Rome, within the framework of the ‘Progetto Integrato Oncologia-Advanced Molecular Diagnostics’ Project (RFPS-2006-2-339723.2).
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.